Uhlmann Price Securities LLC Has $927,000 Stake in Bristol Myers Squibb Company $BMY

Uhlmann Price Securities LLC boosted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 172.9% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 15,841 shares of the biopharmaceutical company’s stock after acquiring an additional 10,036 shares during the quarter. Uhlmann Price Securities LLC’s holdings in Bristol Myers Squibb were worth $927,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in BMY. Swiss RE Ltd. acquired a new position in shares of Bristol Myers Squibb during the 4th quarter worth about $25,000. Physician Wealth Advisors Inc. grew its holdings in Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 202 shares during the last quarter. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb in the 2nd quarter worth approximately $25,000. Bayban acquired a new position in shares of Bristol Myers Squibb during the fourth quarter worth approximately $31,000. Finally, EQ Wealth Advisors LLC acquired a new position in shares of Bristol Myers Squibb during the fourth quarter worth approximately $32,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Trading Up 0.2%

BMY stock opened at $54.10 on Friday. The business has a fifty day moving average price of $57.34 and a 200 day moving average price of $57.09. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The stock has a market capitalization of $110.48 billion, a price-to-earnings ratio of 15.20, a P/E/G ratio of 0.15 and a beta of 0.24. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.16. The firm had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the company posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts expect that Bristol Myers Squibb Company will post 6.32 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.7%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 70.79%.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.05% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages have weighed in on BMY. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Cantor Fitzgerald upped their price objective on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a research report on Wednesday, April 8th. Piper Sandler reiterated an “overweight” rating and issued a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. Finally, Guggenheim restated a “buy” rating and set a $72.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and an average target price of $61.31.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.